Rabbit Polyclonal dik Antibody

中文名： dik抗体
别名： dik,Protein kinase

货号: IPDX35109

Price： ￥1180

50μl 100μl

数量：

大包装询价

验证与应用

应用及物种

WB	咨询技术	Human,Mouse,Rat
IF	咨询技术	Human,Mouse,Rat
IHC	咨询技术	Human,Mouse,Rat
ICC	技术咨询	Human,Mouse,Rat
FCM	咨询技术	Human,Mouse,Rat
Elisa	咨询技术	Human,Mouse,Rat

产品详情

Aliases	dik,Protein kinase
Entrez GeneID	54101
WB Predicted band size	86.4kDa
Host/Isotype	Rabbit IgG
Antibody Type	Primary antibody
Storage	Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species Reactivity	Human, Mouse
Immunogen	This dik antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 510-538 amino acids from the Central region of human dik.
Formulation	Purified antibody in PBS with 0.05% sodium azide.

+ +

All lanes : Anti-dik Antibody (Center)at 1:1000 dilution + HACAT whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ASP1615) at 1/15000 dilution. Observed band size : 90kDa Blocking/Dilution buffer: 5% NFDM/TBST.

参考文献

以下是关于DKK1抗体的3篇代表性文献信息(注：DIK可能为DKK1的笔误，DKK1为肿瘤与骨代谢研究中的关键蛋白)：

1. **《Dickkopf-1 as a Mediator of Tumor Suppression in Multiple Myeloma》**

- 作者：Tian E. et al.

- 摘要：研究揭示了DKK1蛋白在多发性骨髓瘤中抑制骨形成的作用，通过阻断Wnt信号通路导致骨溶解。使用抗DKK1抗体可恢复成骨细胞活性，为治疗骨转移提供依据。

2. **《Anti-DKK1 Antibody Enhances Bone Regeneration in Osteoporosis Models》**

- 作者：Li J. et al.

- 摘要：实验证明抗DKK1抗体通过抑制Wnt通路拮抗剂，显著提高骨质疏松小鼠的骨密度与骨形成率，提示其作为骨疾病治疗靶点的潜力。

3. **《DKK1 Neutralizing Antibody Improves Chemotherapy Efficacy in Solid Tumors》**

- 作者：Wang Y. et al.

- 摘要：研究发现肿瘤微环境中高表达DKK1会抑制免疫应答，联合抗DKK1抗体与化疗可增强T细胞浸润，显著提高结肠癌小鼠模型的生存率。

*注：若您所指为其他特定抗体(如抗双表位抗体或不同靶点)，建议提供更精确的术语以便调整检索方向。部分文献标题与摘要为领域典型研究方向的概括性描述，实际引用时建议通过PubMed/Google Scholar以"DKK1 antibody"或具体疾病关键词查找原文。*

背景信息

**Background of Anti-D Antibodies**

Anti-D antibodies, primarily associated with the Rh blood group system, play a critical role in immunology and transfusion medicine. The Rh system, discovered by Landsteiner and Wiener in 1940. categorizes blood based on the presence (Rh-positive) or absence (Rh-negative) of the RhD antigen on red blood cells. Anti-D antibodies are immunoglobulin G (IgG) molecules that specifically target the RhD antigen.

These antibodies are clinically significant in two contexts: hemolytic disease of the fetus and newborn (HDFN) and transfusion reactions. HDFN occurs when an Rh-negative mother produces anti-D antibodies after exposure to Rh-positive fetal blood, leading to immune-mediated destruction of fetal erythrocytes. Prophylactic administration of anti-D immunoglobulin (RhoGAM) during pregnancy has drastically reduced HDFN incidence by neutralizing fetal RhD antigens before maternal sensitization.

In transfusion medicine, anti-D antibodies can cause acute or delayed hemolytic reactions if Rh-negative individuals receive Rh-positive blood. Their detection is essential in blood typing and compatibility testing. Beyond clinical applications, anti-D antibodies are also utilized in research to study immune responses, B-cell activation, and antigen-antibody interactions.

Overall, anti-D antibodies exemplify the intersection of immunology, genetics, and clinical practice, highlighting their enduring importance in maternal-fetal medicine and transfusion safety.